BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• 

  Drug Development

  COVID-19 Update: Adagio Gunning for EUA and mRNA Boosters Recommended

  Although it looks that we’re on the downside of the COVID-19 pandemic in the U.S., biopharma companies are still working on developing better treatments and preventions.

  March 30, 2022

   · 

  4 min read

   · 

  Mark Terry
• 

  Business

  BioNTech Set to Join Ranks of Largest Drugmakers in the World

  After manufacturing more than 2.6 billion doses of the Comirnaty COVID-19 vaccine together, Pfizer’s partner BioNTech is reporting skyrocketing profits.

  March 30, 2022

   · 

  3 min read

   · 

  Hannah Chudleigh
• 

  Business

  Pursuit of Scientific Challenges Drives New CODA CSO Susan Catalano

  Susan Catalano, Ph.D., joined CODA Biotherapeutics as chief scientific officer after 14 years as CEO of Cognition Therapeutics, the company she founded in 2007 and took public in 2021.

  March 30, 2022

   · 

  5 min read

   · 

  Gail Dutton
• 

  Drug Development

  Study Suggests Far-UV Light Could Save Us from the Next Pandemic

  Researchers have developed a new form of UV light that is safe for people but decreased the level of indoor airborne microbes by more than 98% in less than five minutes.

  March 30, 2022

   · 

  3 min read

   · 

  Mark Terry
• 

  Employer Resources

  How to Manage Gen Z Employees in the Biopharma Industry

  Successfully managing Gen Z employees in the workplace requires knowing about their distinctive traits and the factors that set them apart.

  March 30, 2022

   · 

  5 min read

   · 

  Brandi Marcene
• 

  Drug Development

  Identifying Missing Links - and Why Certain Drugs Don’t Work - in Alzhiemer’s

  A team at the University of California, San Diego developed a drug screening method to help determine why Alzheimer’s drugs fail. The system analyzes disease mechanisms in human neurons.

  March 30, 2022

   · 

  5 min read

   · 

  Mark Terry
• 

  Money on the Move: March 23-29

  This week, money moved in the form of equity financing, upfront partnership payments, nonprofit donations and federal funding.

  March 30, 2022

   · 

  4 min read

   · 

  Hannah Chudleigh
• 

  Drug Development

  Spirit of ALS Patient Drives NeuroSense Mission to Bring PrimeC to Market

  A meeting with an amyotrophic lateral sclerosis (ALS) patient in Israel who could only speak with the assistance of a computer changed the life and direction of NeuroSense CEO Alon Ben-Noon.

  March 30, 2022

   · 

  4 min read

   · 

  Alex Keown
• 

  Biotech Bay

  $100M Richer, Neuron23 Introduces LRRK2 inhibitor for Parkinson’s

  Neuron23 announced today that it closed a $100 million Series C financing round led by SoftBank Vision Fund 2.

  March 30, 2022

   · 

  3 min read

   · 

  Hayley Shasteen
• 

  Business

  Vyant Bio and Organo Therapeutics Join Forces to Solve Parkinson’s

  Vyant Bio and OrganoTherapeutics announced a new partnership between them, with plans to advance research and development efforts in the treatment of Parkinson’s Disease.

  March 30, 2022

   · 

  2 min read

   · 

  Vanessa Doctor, MS